TBI MR Study 3 Houston Methodist

• ClinicalTrials.gov Identifier: NCT02218216
• Recruitment Status: Terminated
• First Posted: August 18, 2014
• Results First Posted: July 24, 2017
• Last Update Posted: July 24, 2017
• Sponsor: GE Healthcare
• Information provided by (Responsible Party): GE Healthcare

Study Description

Brief Summary:

This hypothesis-generating feasibility study to determine potential associations between a broad range of clinical neurological symptoms and Magnetic Resonance Image (MRI), data, and clinical findings involved in mild traumatic brain injury (mTBI). These associations will be examined over the acute and sub-acute period (baseline to 3 months) following injury to provide information useful for optimization of MR pulse sequences for mTBI applications.

The intent of this study is to broadly generate a range of potential mTBI biomarkers detectable using investigational MR pulse sequence technologies. Feasibility data attained in this study may be used for engineering program decision-making and in support of future scientific assessment, engineering development, published research databases or registries mTBI data and images, and other purposes determined by the Sponsor. The results of this study are not intended for use in regulatory submissions.

Subjects will be examined on commercially available MR scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MR pulse sequences optimized by Sponsor

Condition or disease	Intervention/treatment	Phase
Traumatic Brain Injury	Device: MRI Diagnostic	Not Applicable

Detailed Description:

This hypothesis-generating feasibility study is being conducted to determine potential associations between a broad range of clinical neurological symptoms and MR images, data, and clinical findings involved in mild traumatic brain injury (mTBI). These associations will be examined over the acute and sub-acute period (approximately 3 months) following injury to provide information useful for optimization of MR pulse sequences for mTBI applications.

The intent of this study is to broadly generate a range of potential mTBI biomarkers detectable using investigational MR pulse sequence technologies. Feasibility data attained in this study may be used for engineering program decision-making and in support of future scientific assessment, engineering development, published research databases or registries mTBI data and images, and other purposes determined by the Sponsor. The results of this study are not intended for use in regulatory submissions.

Subjects will be examined on commercially available MR scanners using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MR pulse sequences optimized by GEHC.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 16 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Advanced MRI Applications for Mild Traumatic Brain Injury - Study 3
• Study Start Date: September 2014
• Actual Primary Completion Date: May 2015
• Actual Study Completion Date: November 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Experimental: Diagnostic mTBI; MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)	Device: MRI Diagnostic; Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences; Other Name: Magnetic Resonance Image
Placebo Comparator: Experimental: Diagnostic Non mTBI; MRI Diagnostic of Non injured subjects that are closely matched to mTBI	Device: MRI Diagnostic; Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences; Other Name: Magnetic Resonance Image

Outcome Measures

Primary Outcome Measures :

1. mTBI Progression Indicated by Clinical Neurological Characteristics, MRI Images, and Quantitative MRI Data From Novel Software [ Time Frame: Baseline to 3 months ]
   To determine associations between clinical neurological data, MR images, quantitative data from novel software post-processing (sponsor developed software including Volumetry, Kurtosis, Resting State [RS], functional magnetic resonance imaging [fMRI], and additional post-processing modules may be provided

Eligibility Criteria

• Ages Eligible for Study: 15 Years to 50 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Segment 1 (mTBI patient) Inclusion and Exclusion Criteria Inclusion Criteria for mTBI subjects

Subjects included in the main part of this study (Segment 1) will:

1. Be aged ≥15 and ≤50 years old at the time of enrollment;

2. Be diagnosed with mTBI according to the standard diagnostic procedures at the investigational site in a timeframe that meets enrollment criteria for enrollment in one of the first two intervals of the study, as follows:

   1. Meets criteria for enrollment in Encounter 1 (within 72 hours), or
   2. Meets criteria for enrollment in Encounter 2 (within 8±2 days)
3. Be capable of sufficiently clear communication to allow the subject to provide written informed consent, or assent with parental or guardian consent for minors as described in Section 6.3 - Protection of Vulnerable Subjects, for participation in all parts of the study.

Segment 1: Exclusion Criteria for mTBI subjects

Subjects will be excluded that have:

1. Loss of consciousness (LOC) ≥15 minutes;
2. Posttraumatic amnesia lasting ≥24 hr following a recent TBI event;
3. Diagnosis of moderate to severe TBI or GCS <13;
4. Structural brain injury indicated by previous neuroimaging findings;
5. Previous history of moderate to severe TBI;
6. Any previous history of mild TBI within the past 12 months;
7. Previously diagnosed brain white matter disease;
8. History of seizures within the past 10 years;
9. History of self-reported illicit drug abuse (except marijuana) in past 10 years;
10. History of alcohol abuse or dependence (per DSM-IV-TR Diagnostic Criteria);
11. Current primary Axis I or II psychiatric disorders, except for disorders classified as minor and not expected to impact study conduct or integrity (as detailed in Appendix F - Screening for Exclusion based on Axis I or II Disorders):
12. History of brain mass;
13. History of neurosurgery;
14. History of stroke;
15. History of dementia;
16. Known cognitive dysfunction;
17. Known structural brain disease or malformation;
18. Current anti-psychotic or antiepileptic medication usage;
19. That are unable or unwilling to complete study procedures accurately or have any conflict of interest that could affect study results, in the opinion of the investigator;

20. Contraindications to MRI scanning, including:

    1. Current or suspected pregnancy per site clinical practice;
    2. Other conditions that may constitute a hazard to the subject during study participation, determined by the investigator;
    3. Inability to comply with any part of the site's MR safety policy.

Segment 2 (non-TBI subject) Inclusion and Exclusion Criteria Inclusion Criteria for Non-TBI subjects (Segment 2)

All included subjects will:

1. Aged ≥15 and ≤50 years old at the time of enrollment;

2. Be well matched to one or more mTBI patients in Segment 1, in the opinion of the Principal Investigator, with regards to:

   1. Age,
   2. Gender,
   3. Sociodemographic characteristics, and
   4. Handedness.
3. Be capable of sufficiently clear communication to allow the subject to provide written informed consent, or assent with parental or guardian consent for minors as described in Section 6.3 - Protection of Vulnerable Subjects, for participation in all parts of the study.

Exclusion Criteria for Non-TBI subjects (Segment 2)

Subjects will be excluded that:

1. Are currently pregnant based on subject self-report of pregnancy status;
2. Are currently enrolled in another Segment of this study;
3. Require medical care that would be adversely affected or delayed by participating, in the opinion of a physician investigator;
4. Prior diagnosis of mild TBI within the past 12 months;
5. Have structural brain injury indicated by previous neuroimaging findings;
6. Previous history of moderate to severe TBI within the past 10 years;
7. Previously diagnosed brain white matter disease;
8. History of seizures within the past 10 years;
9. History of illicit drug abuse (except marijuana) within the past 10 years
10. History of alcohol abuse or dependence (per DSM-IV-TR Diagnostic Criteria);
11. Current primary Axis I or II psychiatric disorders, except for disorders classified as minor and not expected to impact study conduct or integrity (as detailed in Appendix F - Screening for Exclusion based on Axis I or II Disorders):
12. History of brain mass;
13. History of neurosurgery;
14. History of stroke;
15. History of dementia;
16. Known cognitive dysfunction;
17. Known structural brain disease or malformation;
18. Current anti-psychotic or antiepileptic medication usage;

19. Have contraindications to MRI scanning, including:

    1. Current or suspected pregnancy per site clinical practice;
    2. Other conditions that may constitute a hazard to the subject during study participation, determined by the investigator;
    3. Inability to comply with any part of the site's MR safety policy.

Contacts and Locations

Locations

United States, Texas

Houston Methodist Neurological Institute

Houston, Texas, United States, 77030

Sponsors and Collaborators

GE Healthcare

Investigators

• Principal Investigator: Joseph C Masdeu, MD. PhD; Houston Methodist Neurological Institute

More Information

• Responsible Party: GE Healthcare
• ClinicalTrials.gov Identifier: NCT02218216
• Other Study ID Numbers: 114-2014-GES-0046
• First Posted: August 18, 2014
• Results First Posted: July 24, 2017
• Last Update Posted: July 24, 2017
• Last Verified: June 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by GE Healthcare:

Mild Traumatic Brain Injury

Additional relevant MeSH terms:

Brain Injuries; Brain Injuries, Traumatic; Wounds and Injuries; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Craniocerebral Trauma; Trauma, Nervous System